Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B
Sponsor: Assiut University
Summary
This study aims to evaluate the effect of long-term use of Tenofovir Disoproxil Fumarate (TDF) on bone density in patients with chronic hepatitis B virus (HBV) infection. Tenofovir is a widely used antiviral medication for the treatment of HBV. While it is generally well tolerated, some studies have reported potential adverse effects on bone mineral density, particularly with long-term use. The objective of this research is to assess whether extended TDF therapy is associated with reduced bone density or increased risk of osteopenia or osteoporosis in adult patients with chronic HBV infection. The study will involve clinical evaluation and radiological assessment of bone health using dual-energy X-ray absorptiometry (DEXA) scans, as well as relevant biochemical markers. This investigation will provide important data on the long-term safety profile of Tenofovir in relation to bone health and help guide future clinical decisions for the management of chronic hepatitis B.
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
172
Start Date
2025-05-22
Completion Date
2026-06-01
Last Updated
2025-05-25
Healthy Volunteers
No
Interventions
TDF (Tenofovir)
ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION
Locations (1)
Faculty of Medicine, Assuit
Asyut, Egypt